Overview

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Ketamine